Notice of Abandonment Application No. Applicant(s) 10/583,231 BIRKETT ET AL. Examiner Art Unit LELA S. WILLIAMS 1789

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

The minimum Divise of the communication appear	are on the cover enect mith the correspondence dual coc
This application is abandoned in view of:	
period for reply (including a total extension of time of	illing or Transmission dated, which is after the expiration of the
from the mailing date of the Notice of Allowance (PTOL-85) (a) The issue fee and publication fee, if applicable, was not applicable.	publication fee, if applicable, within the statutory period of three months it.
(b) The submitted fee of \$ is insufficient. A balance of	· ——
	e publication fee, if required by 37 CFR 1.18(d), is \$
(c) The issue fee and publication fee, if applicable, has not	been received.
3. Applicant's failure to timely file corrected drawings as requir Allowability (PTO-37). (a) Proposed corrected drawings were received on(after the expiration of the period for reply. (b) No corrected drawings have been received.	ed by, and within the three-month period set in, the Notice of with a Certificate of Mailing or Transmission dated), which is
 The letter of express abandonment which is signed by the a the applicants. 	attorney or agent of record, the assignee of the entire interest, or all of
 The letter of express abandonment which is signed by an a 1.34(a)) upon the filling of a continuing application. 	attorney or agent (acting in a representative capacity under 37 CFR
6. The decision by the Board of Patent Appeals and Interferer of the decision has expired and there are no allowed claims	nce rendered on and because the period for seeking court reviews.
7. X The reason(s) below:	
See Interview Summary Sheet.	
/Callie E. Shosho/ Supervisory Patent Examiner, Art Unit 1787	/LELA S. WILLIAMS/ Examiner, Art Unit 1789

Petitions to revive under 37 CFR 1.137(a) or (b), or requests to withdraw the holding of abandonment under 37 CFR 1.181, should be promptly filed to minimize any negative effects on patient term.

US Patert and Toldersik Office